Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study
These data demonstrate the heterogeneity in patient characteristics and type of suboptimal responses between switchers and nonswitchers. The results suggest that patients who switched to ruxolitinib had more severe disease or rapid disease progression and that ruxolitinib may provide some clinical benefit in terms of spleen size reduction and hematocrit control.
Authors
- Steffen Koschmieder (ORCID: https://orcid.org/0000-0002-1011-8171)
- Francesco Passamonti (ORCID: https://orcid.org/0000-0001-8068-5289)
- Lambert Busque (ORCID: https://orcid.org/0000-0002-5375-3749)
- Françoise Boyer‐Perrard
- Claire N. Harrison (ORCID: https://orcid.org/0000-0002-3212-920X)
- Wendy Y. Cheng (ORCID: https://orcid.org/0000-0002-8281-2496)
- Clemens Schulte (ORCID: https://orcid.org/0000-0003-2362-3318)
- Marja Nuortti
- Volker Baum
- Timothy Devos (ORCID: https://orcid.org/0000-0002-6881-417X)
- Eyck von der Heyde (ORCID: https://orcid.org/0009-0006-0996-0261)
- Mu Cheng
Institutions
- Novartis (Switzerland) (CH)
- University of Milan (IT)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Rega Institute for Medical Research (BE)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Hôpital Maisonneuve-Rosemont (CA)
- Novartis (Germany) (DE)
- Centre Hospitalier Universitaire d'Angers (FR)
- Praxis für Hämatologie und Onkologie (DE)
- Analysis Group (United States) (US)
- RWTH Aachen University (DE)
- KU Leuven (BE)
Publication Details
- Journal
- Therapeutic Advances in Hematology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1177/20406207251342199
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- Gilead Sciences
- Ariad Pharmaceuticals
- Alexion Pharmaceuticals
- Celgene
- CTI Biopharma
- Incyte
- Galecto
- RWTH Aachen University
- Swedish Orphan Biovitrum
- AOP Orphan
- Sierra Oncology
- Novartis Pharma